Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease, still incurable. The disease is highly heterogenous both genetically and phenotypically. Therefore, developing efficacious treatments is challenging in many aspects because it is difficult to predict the rate of disease progression and stratify the patients to minimize statistical variability in clinical studies. Moreover, there is a lack of sensitive measures of therapeutic effect to assess whether a pharmacological intervention ameliorates the disease. There is also urgency of markers that reflect a molecular mechanism dysregulated by ALS pathology and can be rescued when a treatment relieves the condition. Here, we summarize and discuss biomarkers tested in multicentered studies and across different laboratories like neurofilaments, the most used marker in ALS clinical studies, neuroinflammatory-related proteins, p75ECD, p-Tau/t-Tau, and UCHL1. We also explore the applicability of muscle proteins and extracellular vesicles as potential biomarkers.

Protein biomarkers for the diagnosis and prognosis of Amyotrophic Lateral Sclerosis / Donini, Luisa; Tanel, Raffaella; Zuccarino, Riccardo; Basso, Manuela. - In: NEUROSCIENCE RESEARCH. - ISSN 0168-0102. - 197:(2023), pp. 31-41. [10.1016/j.neures.2023.09.002]

Protein biomarkers for the diagnosis and prognosis of Amyotrophic Lateral Sclerosis

Donini, Luisa;Basso, Manuela
2023-01-01

Abstract

Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease, still incurable. The disease is highly heterogenous both genetically and phenotypically. Therefore, developing efficacious treatments is challenging in many aspects because it is difficult to predict the rate of disease progression and stratify the patients to minimize statistical variability in clinical studies. Moreover, there is a lack of sensitive measures of therapeutic effect to assess whether a pharmacological intervention ameliorates the disease. There is also urgency of markers that reflect a molecular mechanism dysregulated by ALS pathology and can be rescued when a treatment relieves the condition. Here, we summarize and discuss biomarkers tested in multicentered studies and across different laboratories like neurofilaments, the most used marker in ALS clinical studies, neuroinflammatory-related proteins, p75ECD, p-Tau/t-Tau, and UCHL1. We also explore the applicability of muscle proteins and extracellular vesicles as potential biomarkers.
2023
Donini, Luisa; Tanel, Raffaella; Zuccarino, Riccardo; Basso, Manuela
Protein biomarkers for the diagnosis and prognosis of Amyotrophic Lateral Sclerosis / Donini, Luisa; Tanel, Raffaella; Zuccarino, Riccardo; Basso, Manuela. - In: NEUROSCIENCE RESEARCH. - ISSN 0168-0102. - 197:(2023), pp. 31-41. [10.1016/j.neures.2023.09.002]
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0168010223001670-main.pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 1.71 MB
Formato Adobe PDF
1.71 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/405612
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 3
social impact